CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 225 of 275 entries

View as:

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain

Phase: N/A Priority: Normal

NCT ID: NCT01376921 Org: User:

Start: 09/30/12 End: 03/31/15 Due: 03/31/16

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Phase: N/A Priority: Normal

NCT ID: NCT03583346 Org: User:

Start: 08/23/18 End: 07/31/19 Due: 07/31/20

Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency

Phase: N/A Priority: Normal

NCT ID: NCT01060488 Org: User:

Start: 01/31/04 End: - Due: -

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

Phase: N/A Priority: Normal

NCT ID: NCT01100333 Org: User:

Start: 04/30/08 End: 07/31/11 Due: 07/31/12

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00958477 Org: User:

Start: 10/31/08 End: 03/31/11 Due: 03/31/12

A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment

Phase: N/A Priority: Normal

NCT ID: NCT02889380 Org: User:

Start: 08/29/16 End: 04/26/17 Due: 04/26/18

Glucophage Immediate Release (GIR) China Bioequivalence Study

Phase: N/A Priority: Normal

NCT ID: NCT03393208 Org: User:

Start: 01/10/18 End: 01/29/18 Due: 01/29/19

A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Phase: N/A Priority: Normal

NCT ID: NCT01198132 Org: User:

Start: 11/30/09 End: 11/30/15 Due: 11/30/16

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina

Phase: N/A Priority: Normal

NCT ID: NCT01582334 Org: User:

Start: 03/31/13 End: 12/31/15 Due: 12/31/16

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

Phase: N/A Priority: Normal

NCT ID: NCT03725072 Org: User:

Start: 10/30/18 End: 12/05/18 Due: 12/05/19

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01125475 Org: User:

Start: 08/31/10 End: - Due: -

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal

NCT ID: NCT01360827 Org: User:

Start: 08/31/10 End: - Due: -

Effect of Tepotinib on PK of CYP3A Substrate Midazolam

Phase: N/A Priority: Normal

NCT ID: NCT03628339 Org: User:

Start: 08/20/18 End: 10/30/18 Due: 10/30/19

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Phase: N/A Priority: Normal

NCT ID: NCT00933686 Org: User:

Start: 12/31/07 End: 07/31/10 Due: 07/31/11

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia

Phase: N/A Priority: Normal

NCT ID: NCT01400984 Org: User:

Start: 12/31/11 End: 12/31/15 Due: 12/31/16

Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)

Phase: N/A Priority: Normal

NCT ID: NCT01034644 Org: User:

Start: 03/31/10 End: 01/31/11 Due: 01/31/12

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Phase: N/A Priority: Normal

NCT ID: NCT01111019 Org: User:

Start: 03/21/06 End: 01/17/17 Due: 01/17/18

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone

Phase: N/A Priority: Normal

NCT ID: NCT01196156 Org: User:

Start: 09/30/05 End: 12/31/18 Due: 12/31/19

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Phase: N/A Priority: Normal

NCT ID: NCT01982955 Org: User:

Start: 12/23/13 End: 10/14/21 Due: 10/14/22

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Phase: N/A Priority: Normal

NCT ID: NCT01112345 Org: User:

Start: 12/31/09 End: 09/30/12 Due: 09/30/13

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Phase: N/A Priority: Normal

NCT ID: NCT01075841 Org: User:

Start: 03/31/09 End: - Due: -

A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth

Phase: N/A Priority: Normal

NCT ID: NCT01071148 Org: User:

Start: 06/30/09 End: 02/28/14 Due: 02/28/15

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece

Phase: N/A Priority: Normal

NCT ID: NCT01363674 Org: User:

Start: 04/30/13 End: 12/31/15 Due: 12/31/16

An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients

Phase: N/A Priority: Normal

NCT ID: NCT01080742 Org: User:

Start: 01/31/10 End: 12/31/11 Due: 12/31/12

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients

Phase: N/A Priority: Normal

NCT ID: NCT01508325 Org: User:

Start: 12/31/11 End: 04/30/14 Due: 04/30/15

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain	NCT01376921	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2012-09-30	2015-03-31	2016-03-31	-	-	2025-07-14
Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)	NCT03583346	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-08-23	2019-07-31	2020-07-31	-	-	2025-07-14
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency	NCT01060488	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2004-01-31	-	-	-	-	2025-07-14
GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)	NCT01100333	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-04-30	2011-07-31	2012-07-31	-	-	2025-07-14
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer	NCT00958477	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-10-31	2011-03-31	2012-03-31	-	-	2025-07-14
A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment	NCT02889380	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2016-08-29	2017-04-26	2018-04-26	-	-	2025-07-14
Glucophage Immediate Release (GIR) China Bioequivalence Study	NCT03393208	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-01-10	2018-01-29	2019-01-29	-	-	2025-07-14
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly	NCT01198132	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-11-30	2015-11-30	2016-11-30	-	-	2025-07-14
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina	NCT01582334	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-03-31	2015-12-31	2016-12-31	-	-	2025-07-14
Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib	NCT03725072	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-10-30	2018-12-05	2019-12-05	-	-	2025-07-14
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects	NCT01125475	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-08-31	-	-	-	-	2025-07-14
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT01360827	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-08-31	-	-	-	-	2025-07-14
Effect of Tepotinib on PK of CYP3A Substrate Midazolam	NCT03628339	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-08-20	2018-10-30	2019-10-30	-	-	2025-07-14
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome	NCT00933686	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-12-31	2010-07-31	2011-07-31	-	-	2025-07-14
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia	NCT01400984	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-12-31	2015-12-31	2016-12-31	-	-	2025-07-14
Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)	NCT01034644	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-03-31	2011-01-31	2012-01-31	-	-	2025-07-14
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children	NCT01111019	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2006-03-21	2017-01-17	2018-01-17	-	-	2025-07-14
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone	NCT01196156	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2005-09-30	2018-12-31	2019-12-31	-	-	2025-07-14
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)	NCT01982955	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-12-23	2021-10-14	2022-10-14	-	-	2025-07-14
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters	NCT01112345	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-12-31	2012-09-30	2013-09-30	-	-	2025-07-14
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck	NCT01075841	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-03-31	-	-	-	-	2025-07-14
A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth	NCT01071148	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-06-30	2014-02-28	2015-02-28	-	-	2025-07-14
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece	NCT01363674	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-04-30	2015-12-31	2016-12-31	-	-	2025-07-14
An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients	NCT01080742	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-01-31	2011-12-31	2012-12-31	-	-	2025-07-14
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients	NCT01508325	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-12-31	2014-04-30	2015-04-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance